SDGR
Schrödinger, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.34
P/S
3.34
EV/EBITDA
-8.56
DCF Value
$-47.39
FCF Yield
1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
55.7%
Operating Margin
-65.2%
Net Margin
-40.4%
ROE
-29.5%
ROA
-14.3%
ROIC
-30.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $87.2M | $32.5M | $0.44 |
| FY 2025 | $255.9M | $-103.3M | $-1.41 |
| Q3 2025 | $54.3M | $-32.8M | $-0.45 |
| Q2 2025 | $54.8M | $-43.2M | $-0.59 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.62
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.